What top creators are saying about Eli Lilly and Company(LLY)— Page 2

Viewed as a bio-compute play due to massive GPU power holdings.

Strong bio/consumer drug play that recently hit new all-time highs.

Hit $1 trillion valuation milestone driven by expanded insurance coverage for Zepbound.

Launched a $500 million AI biotech fund to accelerate drug development and provides diversified exposure to the sector.

Bypassing cloud providers to spend $1 billion directly on NVIDIA GPUs to secure private compute supply.

The investigational drug Retatrutide shows high efficacy, but the company faces significant litigation risks and side-effect concerns.

Identified as a potential candidate to capture the ongoing 'peptide freight train' trend.

Frontrunner in the weight-loss drug space with potential to become the first trillion-dollar biotech company.

Highlighted as a key player in the high-demand GLP-1 weight loss market being distributed through telehealth channels.

Strategic partnership with Hims allows for distribution of branded medications; future pipeline includes next-gen drug Retatrutide.

Mentioned as a partner for branded GLP-1 distribution through the Hims & Hers platform.

Producer of GLP-1 medications and active in the Alzheimer's drug market, benefiting from the link between metabolic health and cognitive function.

Lighter enforcement on compounded alternatives creates a competitive headwind for their branded GLP-1 drugs.

Dominant player in the GLP-1 market with a recurring revenue model due to 'forever drug' nature; pipeline includes Retatrutide which may offer superior weight loss results.

Developing Retatrutide, a triple agonist showing dramatic weight loss and liver fat reduction results.

Retatrutide showing massive improvements in weight loss and liver health; company is currently supply-constrained rather than demand-constrained.

Described as a trillion-dollar safe bet in the longevity and peptide market.

New clinical data for Retatrutide shows superior weight loss and health markers, positioning it as a premium high-margin drug.

Described as a 'killer' stock due to dominance in the weight-loss drug market.

Primary benefactor of the peptide and GLP-1 weight-loss drug trend, currently trading at a slight discount.

GLP-1 drugs show significant clinical benefits for heart and brain health beyond weight loss, though risks like NAION should be monitored.

The popularity of GLP-1 drugs represents a massive market opportunity and a shift toward metabolic health abundance.

Applying AI to drug design, illustrating the 'Jevons Paradox' where efficiency in AI-driven research increases the overall demand for the resource.

Partnered with HIMS to provide access to its weight-loss drug Zepbound.

Resolved supply chain issues and is utilizing telehealth partners to capture extreme demand for its superior Tirzepatide product.

Dominating the cardiometabolic space with GLP-1 drugs and bypassing pharmacy friction through the LillyDirect DTC platform; developing 'triple-acting' molecules for 2025/2026.

The speaker is highly bullish on the massive expansion of the Total Addressable Market (TAM) for GLP-1s, citing applications in cardiovascular health, addiction, and chronic diseases beyond just weight loss.

A key player in the GLP-1 supply chain expected to benefit from the drug's expansion into non-obesity medical indications.

A primary public proxy for the rapidly growing GLP-1 and peptide market trend.

Bullish outlook due to the expansion of GLP-1 medications into broader chronic disease prevention and metabolic health.

Speculation regarding a potential future partnership with HIMS for peptide-related treatments.

Utilizing AI for massive data set analysis in clinical trials to improve profit margins.

Partnered with Insilico Medicine for AI-driven drug discovery which shows high clinical trial success rates.

Aggressively partnering with AI-first biotech firms like Insilico Medicine to collapse drug discovery timelines.

Key player in the GLP-1 market which is viewed as the entry point for reversing aging.

Leader in AI-driven drug discovery with a recent price reset providing a potential entry point.

Partnering with Amazon Pharmacy for same-day delivery of GLP-1 medications, leveraging Amazon's logistics network to capture the metabolic health market.

Partnership with Amazon Pharmacy for same-day delivery of new GLP-1 pill Foundayo provides a major growth lever.

Developing Retatrutide, a powerful upcoming triple agonist drug currently in Phase 3 trials.

Becoming a 'token factory' by using supercomputers and AI to revolutionize drug discovery.

As GLP-1 drugs gain social momentum, regulatory shifts may create moats for large pharmaceutical companies capable of navigating the clinical trial process.

Potential future distribution partnership with HIMS; competitor in the weight loss pill and peptide market.

Up 4% on news of a new oral weight-loss pill, Fondayo, expanding its market reach.

Showing positive momentum as a notable green performer.

Strategic $2.75 billion collaboration with Insilico Medicine to acquire AI-vetted drug candidates, potentially securing new GLP-1 assets.

Part of the 'health-maxing' and longevity investment theme involving peptides and weight loss.

Included in the curated model portfolio focusing on high-conviction hardware and infrastructure names.

Deeply integrated with the U.S. legislative process and highlighted as a major corporate donor to influential health committee members.

Dominant in weight-loss market with Zepbound; viewed as a long-term winner despite a recent 6% daily dip.

Positioned to benefit from regulatory crackdowns on unregulated peptides and the development of next-generation drugs like Retatrutide.